RED
BANK, N.J., June 3, 2022
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a
biopharmaceutical company dedicated to intercepting and preventing
immune-mediated disease, today announced Dr. Jeffrey Bluestone's
decision to step down as a director on the Company's board of
directors to focus on his other commitments, including his role as
President and Chief Executive Officer of Sonoma Biotherapeutics.
Dr. Bluestone will continue as Scientific Advisor to the
Company.
"It has been an absolute honor to work alongside Dr. Bluestone,
who has drawn from his wealth of expertise and experience as a
luminary in immune tolerance research to support Provention's
mission during his tenure as a fellow director," said Wayne Pisano, Chairman of Provention's board of
directors.
"Having given birth to teplizumab more than three decades ago,
it has been an exhilarating and personally fulfilling experience
supporting this therapeutic candidate's advanced stages of
development over the past three years as a director of Provention
Bio. I have been fortunate to be involved in the development of
teplizumab, from the earliest discovery research to its current
status as a Biological License application under review by the
United States Food and Drug Administration. After spending over 40
years in this endeavor, I await United States Food and Drug
Administration's decision on the teplizumab Biological License
application resubmission hoping for a time when individuals at risk
of clinical type 1 diabetes, will have new therapies to treat this
devastating disease," said Dr. Bluestone.
"On behalf of Provention's board of directors, employees and
shareholders, I would like to express our deepest gratitude to Jeff
for his key contributions to Provention as a director and look
forward to his continued contributions as a Scientific Advisor to
the Company. We wish him all the best in his ongoing exceptional
career and future research and development endeavors," stated
Ashleigh Palmer, Chief Executive
Officer, director and co-founder, Provention Bio.
About Provention Bio, Inc.:
Provention Bio, Inc.
(Nasdaq: PRVB) is a biopharmaceutical company focused on advancing
the development of investigational therapies that may intercept and
prevent debilitating and life-threatening immune-mediated diseases.
The Biologics License Application (BLA) for teplizumab, its lead
investigational drug candidate, for the delay of progression to
Stage 3 clinical type 1 diabetes in at-risk individuals has been
filed by the U.S. Food and Drug Administration (FDA). The Company's
pipeline includes additional clinical-stage product candidates that
have demonstrated in pre-clinical or clinical studies
proof-of-mechanism and/or proof-of-concept in other autoimmune
diseases, including celiac disease and lupus. Visit
www.ProventionBio.com for more information and follow us on
Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc.
uses its website, www.proventionbio.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation F.D. Such disclosures
will be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contact:
Robert
Doody, VP, Investor Relations
rdoody@proventionbio.com
484-639-7235
Media Contact:
Kaelan
Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-announces-update-to-board-of-directors-301560700.html
SOURCE Provention Bio, Inc.